A first-in-human Phase 1/1b randomized trial evaluating the safety and immunogenicity of a respiratory syncytial virus (RSV) virus-like particle subunit vaccine (IVX-121) in healthy young and older adults

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease in all age groups, with substantial burden in older adults. Here, we report the safety and immunogenicity of IVX-121, an investigational virus-like particle vaccine against RSV. This Phase 1/1b trial (EudraCT num...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ilse De Coster, Isabel Leroux-Roels, Kanchanamala Withanage, Leen Suykens, Valentino D’Onofrio, Geert Leroux-Roels, Pierre van Damme, Max Ciarlet, Elizabeth M. Adams, Wasima Rida, Judy Wen, Margaret MacDonald, Jennifer Price, Niranjan Kanesa-thasan
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2026-12-01
Edice:	Human Vaccines & Immunotherapeutics
Témata:	IVX-121 respiratory syncytial virus RSV vaccine virus-like particle
On-line přístup:	https://www.tandfonline.com/doi/10.1080/21645515.2026.2633021
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!